医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 5.14 | 21.42 | 15167.42 | | 300049 | 福瑞股份 | 20.00 | 8.88 | 14112.13 | | 002873 | 新天药业 | 10.04 | 21.73 | 12756.46 | | 300003 | 乐普医疗 | 7.50 | 5.21 | 11879.51 | | 600645 | 中源协和 | 5.87 | 7.07 | 10630.01 | | 300204 | 舒泰神 | 3.85 | 5.17 | 10605.35 | | 688189 | 南新制药 | 20.03 | 13.24 | 10160.34 | | 000538 | 云南白药 | 1.57 | 1.14 | 7852.22 | | 600557 | 康缘药业 | 2.15 | 5.69 | 7699.12 | | 002082 | 万邦德 | 10.01 | 3.49 | ...

Market Performance - The pharmaceutical commercial sector increased by 0.67% compared to the previous trading day, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3728.03, up 0.85%, while the Shenzhen Component Index closed at 11835.57, up 1.73% [1] Individual Stock Performance - Saily Medical (603716) closed at 29.87, up 5.14%, with a trading volume of 409,100 shares and a transaction value of 1.187 billion [1] - Yifeng Pharmacy (603939) closed at 23.87, up 2.14%, with a trading volume of 100,900 shares and a transaction value of 239 million [1] - Other notable performers include Yaoyigou (300937) at 30.10 (+2.03%), Laobaixing (603883) at 18.43 (+1.26%), and Haiwang Biological (000078) at 2.69 (+1.13%) [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 10.8635 million from institutional investors, while retail investors saw a net inflow of 12.0341 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Detailed Capital Flow for Selected Stocks - Saily Medical had a net outflow of 95.4222 million from institutional investors, while retail investors contributed a net inflow of 45.8725 million [3] - Guoyao Co. (600511) saw a net inflow of 38.7702 million from institutional investors, but a net outflow of 35.7166 million from retail investors [3] - Other stocks like Zhejiang Zhenyuan (000705) and Ruikang Pharmaceutical (002589) also showed varied capital flows, indicating differing investor sentiments across the sector [3]

金融界消息，根据中登公司数据显示，截至上周最后一个交易日（8月15日），塞力医疗股东质押比例 占总股本9.23%，位居两市第989位。 数据显示，塞力医疗股东共质押1930.00万股，分为5笔，其中无限售股1930.00万股，质押总市值5.48亿 元。 资料显示，塞力斯医疗科技集团股份有限公司的主营业务是体外诊断试剂、体外诊断仪器的销售业务。 公司的主要产品是单纯销售、集约化IVD、集约化SPD。公司较早将IVD集约化业务升级布局SPD运营 业务，取得先发优势。同时基于公司早些年强大的IVD运营根基，凭借医疗供应领域二十余年的经验累 积和过硬实力荣登中国物流与采购联合会医疗器械供应链50强获奖企业名单，同时被授予《医药产品医 院院内物流服务规范》团体标准试点单位。公司董事长为温伟，总经理为王政。 从股票走势来看，塞力医疗近一年上涨 319.65%。 来源：金融界 ...

Core Viewpoint - The company, Saily Medical, is actively developing digital therapies in the field of brain science, particularly focusing on mental health management through innovative software solutions and strategic collaborations with leading institutions and technology partners [1]. Group 1: Company Developments - As of August 15, 2025, Saily Medical's stock closed at 28.41 yuan, down 3.69%, with a turnover rate of 18.76% and a trading volume of 358,300 hands, resulting in a transaction amount of 1.017 billion yuan [1]. - The company has established a digital management software named "Haisi Lingxi" aimed at assisting in the management of major mental illnesses such as depression and bipolar disorder, leveraging AI and internet technologies [1]. - In April 2025, Saily Medical launched an AI diagnostic technology research center (TAIDxLab) in Shanghai, focusing on rapid molecular diagnostics for infections and critical conditions, as well as digital therapies for brain science [1]. Group 2: Strategic Collaborations - Saily Medical has partnered with Huawei Technologies and a key national laboratory to explore the application of brain science models in psychiatry, aiming to transition the industry from experience-driven to data-driven approaches [1]. - The collaboration with Zhejiang University First Affiliated Hospital's Mental Health Center is part of a national key project for the prevention and treatment of common mental disorders, which commenced in April 2024 [1]. - The partnership aims to build a closed-loop system for secure and reliable medical data processing, integrating resources from medical institutions, pharmaceutical companies, and regulatory bodies [1]. Group 3: Market Activity - On August 15, 2025, the net outflow of main funds from Saily Medical was 136 million yuan, accounting for 13.35% of the total transaction amount [2][3]. - Retail investors showed a net inflow of 147 million yuan, representing 14.49% of the total transaction amount, indicating strong interest from individual investors despite the outflow from institutional funds [3].

Group 1 - The stock price of Saily Medical (603716) closed at 28.41 yuan as of August 15, 2025, representing a 2.93% increase from the previous week's price of 27.6 yuan [1] - The highest intraday price reached 31.31 yuan on August 13, 2025, while the lowest intraday price was 27.55 yuan on August 11, 2025 [1] - The total market capitalization of Saily Medical is currently 5.427 billion yuan, ranking 18th out of 31 in the pharmaceutical commercial sector and 3060th out of 5152 in the A-share market [1] Group 2 - The actual controller of the company, Mr. Wen Wei, has completed the release of the pledge on 3,000,000 shares, reducing his pledged shares to 5,300,000, which is 55.01% of his holdings and 2.77% of the total share capital [1] - The cumulative pledged shares by the controlling shareholder, Saihai Technology, and Mr. Wen Wei amount to 19,300,000 shares, representing 61.71% of their total holdings and 10.10% of the total share capital [1] Group 3 - The convertible bond "Saily Convertible Bond" will pay interest on August 21, 2025, for the period from August 21, 2024, to August 20, 2025 [2] - The total issuance amount of the convertible bond is 543.31 million yuan, with an interest payment of 2.50 yuan per bond (including tax) [2] - The interest payment record date is August 20, 2025, with the ex-dividend date and payment date both set for August 21, 2025 [2]

证券之星消息，塞力医疗(603716)08月15日在投资者关系平台上答复投资者关心的问题。 塞力医疗回复：尊敬的投资者，您好！早在2022年，塞力医疗便积极布局脑科学数字疗法领域，公司依 托旗下专注于智慧医疗数智转型及创新应用场景的子公司——海思太科（武汉）医疗科技有限公司，联 合浙江大学医学院附属第一医院精神卫生中心部署精神疾病全病程数智系统"海思灵曦"。作为面向国家 2030"脑计划与类脑研究"项目的重要成果，"海思灵曦"是针对抑郁症、双相情感障碍等主要精神疾病的 数字化辅助管理软件。该软件依托人工智能及互联网技术构建脑科学及类脑研究知识图谱，形成了面向 科研人员、医生和患者三方的前端用户功能工具平台。2024年4月，海思太科与浙大一院精神卫生中心 开启脑计划2030-脑计划与类脑研究"常见多发病防治研究"国家级重点专项计划，并同时在全国14家头 部医疗机构多中心同步开展。2025年初，塞力医疗联合华为技术、脑机智能全国重点实验室胡少华教授 团队签署精神医学数字疗法的战略合作框架。三方以华为算力基础设施为支撑，结合脑机智能全国重点 实验室科研资源与临床数据，探索脑科学大模型在精神医学中的应用，推动行业从经 ...

Core Viewpoint - The company, Saily Medical (603716.SH), is actively investing in the field of digital therapies for brain science, focusing on mental health management through innovative technology and strategic partnerships [1] Group 1: Company Initiatives - In 2022, Saily Medical began its strategic layout in the digital therapy sector for brain science, leveraging its subsidiary, Haisitai Medical Technology Co., Ltd., to develop a comprehensive digital management system for mental illnesses [1] - The "Haisilingxi" system, developed in collaboration with Zhejiang University First Affiliated Hospital's Mental Health Center, targets major mental disorders such as depression and bipolar disorder [1] - A national key project under the "Brain Plan 2030" was initiated in April 2024, involving multi-center studies across 14 leading medical institutions [1] Group 2: Strategic Partnerships - In early 2025, Saily Medical signed a strategic cooperation framework with Huawei Technologies and Professor Hu Shaohua's team from the National Key Laboratory of Brain-Machine Intelligence to explore the application of brain science models in psychiatry [1] - The collaboration aims to transition the industry from experience-driven to data-driven approaches, utilizing Huawei's computational infrastructure and clinical data [1] Group 3: Technological Development - By April 2025, Saily Medical established an AI diagnostic technology research center (TAIDx Lab) in Shanghai, focusing on rapid molecular diagnostics for infections and critical conditions, as well as digital therapies for brain science [1] - The lab is equipped with Huawei's Ascend AI cluster and Kunpeng servers to efficiently process large volumes of data, creating a secure and closed-loop system involving medical institutions, pharmaceutical companies, and regulatory bodies [1] - Future efforts will concentrate on advancing technology development and application to build core competitive advantages through technological barriers [1]

证券之星消息，8月14日医药商业板块较上一交易日下跌1.35%，塞力医疗领跌。当日上证指数报收于 3666.44，下跌0.46%。深证成指报收于11451.43，下跌0.87%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603939 | 益丰药房 | 1562.54万 | 9.35% | -99.62万 | -0.60% | -1462.92万 | -8.75% | | 000028 | 国药一致 | 577.41万 | 5.26% | -431.37万 | -3.93% | -146.04万 | -1.33% | | 000411 | 英特集团 | 503.55万 | 6.47% | 507.34万 | 6.52% | -- 1010.88万 | -13.00% | | 002788 | 鹭燕医药 | 240.24万 | 4.17% | 602.82万 | 10.47% | -8 ...

截至2025年8月13日15时，塞力医疗最新股价为31.09元，较前一交易日收盘价上涨1.91元。当日开盘价 为29.04元，最高触及31.31元，最低下探28.59元，成交量为55.62万手，成交金额达16.71亿元。 风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 塞力医疗属于医药商业板块，公司主营业务为医疗商业和工业业务。2024年财务数据显示，其商业业务 收入占比达97.09%，工业业务收入占比2.91%。 来源:金融界 8月12日晚间，公司发布公告称实际控制人温伟已办理完成300万股股份的解除质押手续。本次解除质押 后，温伟累计质押股份数降至530万股，占其持股比例的55.01%。公司控股股东及实际控制人合计质押 股份数为1930万股，占公司总股本的10.1%。 8月13日主力资金净流入1.09亿元，占流通市值的1.84%。近五个交易日主力资金累计净流入1.44亿元， 占流通市值的2.42%。 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]